Empire Asset Management issued a note on Insulet Corporation (NASDAQ: PODD) after recent analysis of the company's core business capabilities, specifically its insulin delivery pump "OmniPod." Analysts initiated coverage of Insulet with a Sell...
WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) announced that MannKind has
withdrawn its offer to employ Duane DeSisto as its President and Chief Executive
Officer as a consequence of objections raised by Insulet Corporation, the former
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced it has partnered with Glooko1, the leader in diabetes management mobile and...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Insulet (PODD):
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.